Trial · NCT07408193
The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.
NCT07408193, Early phase 1, Recruiting, National and Kapodistrian University of Athens
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain. Trials, record NCT07408193. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07408193
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Coadministration of Lidocaine and Ketamine in Opioid-Refractory Chronic Cancer-Related Pain.
- NCT number
- NCT07408193
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 24 participants, estimated
- Lead sponsor
- National and Kapodistrian University of Athens
- Conditions
- Opioid-Refractory Chronic Cancer-Related Pain
- Interventions
- Lidocaine and Ketamine Infusion, Active Placebo (Midazolam) Infusion
- First posted
- 2026-02-13
- Last updated
- 2026-07-07
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in the Worst Pain During the Last 24 Hours on an 11-Point, 0 to 10, Numerical Rating Scale | Baseline (immediately before the first LK or placebo infusion) and one week after the second infusion. | Question 3 of the Brief Pain Inventory - Short Form, where 0 is equivalent to no pain and 10 indicates the worst possible pain. |
| Secondary | Changes in the Score of Pain Intensity of the Brief Pain Inventory - Short Form | Baseline (before the first LK or placebo infusion), before the second infusion (LK or placebo), and, one week after the second infusion (LK or placebo). | Assesses changes in patient-reported pain severity, including worst, least, average pain over the past 24 hours, and current pain ("pain right now"). |
| Secondary | Change in the Proportion of Patients Achieving 2-Point Reduction on Worst and Least Pain of the Brief Pain Inventory - Short Form | Baseline (before the first LK or placebo infusion), before the second infusion (LK or placebo), and, one week after the second infusion (LK or placebo). | Evaluates the proportion of patients achieving a clinically significant improvement, defined as a ≥2-point reduction in worst and least pain on the Brief Pain Inventory. |
| Secondary | Change in the Score of the Interference Scale of the Brief Pain Inventory - Short Form | Baseline (before the first LK or placebo infusion), before the second infusion (LK or placebo), and, one week after the second infusion (LK or placebo). | Measures changes in the degree to which pain interferes with daily functioning, mood, sleep, work, and social activities. |
| Secondary | Change in total Oral Morphine Equivalents Consumption of the Previous Week | Baseline (before the first LK or placebo infusion), before the second infusion (LK or placebo), and, one week after the second infusion (LK or placebo). | Assesses changes in total opioid use by calculating the weekly oral morphine equivalent dose consumed by each participant. |
| Secondary | Immediate Analgesic Effect of the Infusion (LK or placebo) | Before the infusion and one hour after infusion termination. | Evaluated using question 6 of the Brief Pain Inventory - Short Form (pain right now) |
| Secondary | Change in the Score of the Beck Depression Inventory | Baseline (immediately before the first LK or placebo infusion) and one week after the second infusion. | Measures changes in depressive symptom severity associated with treatment over the course of the study. Beck Depression inventory is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. Scores range from 0 to 63, where higher score indicates more depressive symptoms. |
| Secondary | Rating of Overall Improvement Using Patient Global Impression of Change Scale | one week after the second (LK or placebo) infusion | Assesses the patient's overall perceived improvement in pain and function following the treatment. PGIC is a 7 point scale depicting a patient's rating of overall improvement. Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse." |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers24
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07408193
GET https://conductscience.org/api/trials/v1/NCT07408193/papers?page=2